Even if it's not a huge purchase, we think it was good to see that Aaron Fletcher, the Independent Director of Cue Biopharma, Inc. (NASDAQ:CUE) recently shelled out US$83k to buy stock, at US$12.64 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results